Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rigel Pharmaceuticals
Biotech
Lilly pulls out of CNS portion of $960M collab with Rigel
Eli Lilly has pulled out of the CNS portion of a $960 million biobucks deal centered on Rigel’s RIPK1 inhibitors.
James Waldron
Nov 5, 2025 7:00am
Another Biogen exec hitches ride to Voyager —Chutes & Ladders
Mar 15, 2024 9:30am
Rigel bets $230M on Forma's leukemia drug
Aug 2, 2022 4:01pm
Eli Lilly hands over $125M to Rigel for experimental drug deal
Feb 18, 2021 8:05am
Rigel falsely claims FDA approval in ‘website error’
Apr 13, 2018 7:42am
Rigel slips as fostamatinib trial misses the mark
Apr 3, 2018 9:38am
